Immunogenicity of FourPlasmodium falciparumPreerythrocytic Antigens inAotus lemurinusMonkeys

Abstract

Aotus lemurinus monkeys were immunized with pools of either lipid-tailed peptides injected in PBS or peptides in Montanide ISA-51, all derived from four Plasmodium falciparum pre-erythrocytic antigens, namely, LSA1, LSA3, SALSA, and STARP. These formulations were well tolerated. Their immunogenicity was demonstrated by the induction of both B- and T-cell responses to most of the peptides studied (of the 12, 10 induced antibody production, 9 induced T-cell proliferative responses, and all 12 induced gamma interferon secretion). Immune responses proved to be long lasting, since some were still detectable 210 days after immunization. Of particular importance is the fact that B- and T-cell responses elicited in this way by synthetic peptides were specific for native parasite proteins on P. falciparumsporozoites and liver stage parasites.

Immunogenicity and protective efficacy of Plasmodium falciparum liver‐stage Ag‐3 in Aotus lemurinus griseimembra monkeys

“…Sauzet et al, manuscript in preparation). Our study confirm previous evidence that LSA‐3 is a strong inducer of this cytokine 10, 12, 13. Aotus previously immunized using LSA‐3‐729 lipopeptide formulations also developed high IFN‐γ and significant Ab responses 12.…”

Nanotechnology in vaccine delivery

“…ISA 51 and 720 have both been shown to induce high antibody titers and CTL responses in a variety of animal species [176][177][178][179]. In many cases, the response was greater than that achieved using other types of adjuvants [85,173,173,176,179].…”

“…ISA 51 and 720 have both been shown to induce high antibody titers and CTL responses in a variety of animal species [176][177][178][179]. In many cases, the response was greater than that achieved using other types of adjuvants [85,173,173,176,179]. These emulsions have been in phase I and/or II clinical trials for vaccines against malaria, HIV and various cancers [173][174][175][180][181][182][183][184].…”

La Malaria: Estrategias Actuales Para El Desarrollo De Una Vacuna Efectiva

“…Estas especies se mantienen en bioterios diseñados para los programas tanto de zoocría, como de experimentación pre-clínica. Los trabajos descritos se han realizado bajo estándares internacionales de BPL [30][31][32][33] .…”

“…Se ha estudiado un número significativo de antígenos de los diferentes estadios de desarrollo del parásito: fase pre-eritrocítica 29,32,34,35 , fase sanguínea sexual 30,36,37 , y fase esporogónica, tanto del P. falciparum como de P.vivax (Tabla 1). Mientras algunos corresponden a antígenos desarrollados y producidos por nuestro grupo en Colombia, otros han sido producidos por grupos de investigación extranjeros y evaluados en el Centro Internacional de Vacunas en Cali, en diferentes fases de su desarrollo (Tabla 2).…”